| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombectomy | 29 | 2026 | 110 | 5.070 |
Why?
|
| Embolization, Therapeutic | 21 | 2026 | 225 | 4.700 |
Why?
|
| Hematoma, Subdural, Chronic | 10 | 2025 | 13 | 3.530 |
Why?
|
| Meningeal Arteries | 12 | 2025 | 15 | 2.590 |
Why?
|
| Endovascular Procedures | 22 | 2026 | 775 | 2.400 |
Why?
|
| Stroke | 24 | 2026 | 1049 | 2.390 |
Why?
|
| Bone Screws | 8 | 2015 | 52 | 2.040 |
Why?
|
| Stents | 17 | 2026 | 780 | 1.940 |
Why?
|
| Atlanto-Axial Joint | 8 | 2015 | 21 | 1.740 |
Why?
|
| Intracranial Aneurysm | 9 | 2026 | 83 | 1.620 |
Why?
|
| Tinnitus | 2 | 2023 | 23 | 1.530 |
Why?
|
| Treatment Outcome | 66 | 2026 | 13011 | 1.370 |
Why?
|
| Neurosurgical Procedures | 6 | 2020 | 317 | 1.070 |
Why?
|
| Aged, 80 and over | 38 | 2026 | 6922 | 1.020 |
Why?
|
| Propensity Score | 8 | 2025 | 266 | 1.000 |
Why?
|
| Cranial Sinuses | 2 | 2023 | 14 | 0.970 |
Why?
|
| Cerebral Hemorrhage | 6 | 2025 | 157 | 0.950 |
Why?
|
| Aged | 56 | 2026 | 21279 | 0.910 |
Why?
|
| Magnesium Sulfate | 1 | 2024 | 51 | 0.860 |
Why?
|
| Retrospective Studies | 52 | 2026 | 17703 | 0.830 |
Why?
|
| Cervical Vertebrae | 2 | 2015 | 117 | 0.830 |
Why?
|
| Middle Aged | 59 | 2026 | 28911 | 0.820 |
Why?
|
| Drainage | 2 | 2016 | 253 | 0.790 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 162 | 0.790 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 228 | 0.770 |
Why?
|
| Cerebral Revascularization | 3 | 2023 | 22 | 0.770 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2026 | 37 | 0.680 |
Why?
|
| Anesthesia, General | 4 | 2026 | 128 | 0.680 |
Why?
|
| Hematoma, Subdural | 2 | 2023 | 28 | 0.680 |
Why?
|
| Humans | 99 | 2026 | 131967 | 0.650 |
Why?
|
| Brain Ischemia | 5 | 2023 | 261 | 0.650 |
Why?
|
| Spinal Fusion | 7 | 2018 | 118 | 0.650 |
Why?
|
| Craniotomy | 3 | 2016 | 102 | 0.600 |
Why?
|
| Carotid Stenosis | 3 | 2026 | 107 | 0.590 |
Why?
|
| Cervical Atlas | 2 | 2016 | 8 | 0.590 |
Why?
|
| Male | 64 | 2026 | 65357 | 0.580 |
Why?
|
| Joint Instability | 3 | 2013 | 57 | 0.570 |
Why?
|
| Female | 65 | 2026 | 71316 | 0.560 |
Why?
|
| Vertebral Artery | 3 | 2014 | 19 | 0.560 |
Why?
|
| Angioplasty | 4 | 2024 | 66 | 0.540 |
Why?
|
| Registries | 13 | 2026 | 1598 | 0.530 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2026 | 2123 | 0.490 |
Why?
|
| Arthrodesis | 2 | 2015 | 14 | 0.490 |
Why?
|
| Neurosurgery | 2 | 2014 | 75 | 0.480 |
Why?
|
| Tranexamic Acid | 1 | 2016 | 31 | 0.470 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 48 | 0.460 |
Why?
|
| Anticoagulants | 3 | 2023 | 597 | 0.440 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 76 | 0.420 |
Why?
|
| Angioplasty, Balloon | 2 | 2025 | 128 | 0.420 |
Why?
|
| Aneurysm, Ruptured | 2 | 2015 | 34 | 0.400 |
Why?
|
| Spinal Injuries | 1 | 2013 | 33 | 0.400 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 132 | 0.400 |
Why?
|
| Arachnoid | 2 | 2023 | 9 | 0.390 |
Why?
|
| Betacoronavirus | 3 | 2020 | 287 | 0.380 |
Why?
|
| Spinal Cord | 2 | 2021 | 269 | 0.370 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 148 | 0.370 |
Why?
|
| Time-to-Treatment | 5 | 2026 | 215 | 0.370 |
Why?
|
| Heparin | 1 | 2013 | 206 | 0.370 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 200 | 0.360 |
Why?
|
| Thrombolytic Therapy | 2 | 2025 | 207 | 0.340 |
Why?
|
| Aneurysm, False | 1 | 2012 | 84 | 0.340 |
Why?
|
| Arteries | 1 | 2012 | 210 | 0.340 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 366 | 0.340 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 180 | 0.330 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 378 | 0.330 |
Why?
|
| Vascular Diseases | 1 | 2012 | 155 | 0.330 |
Why?
|
| Radial Artery | 3 | 2026 | 34 | 0.330 |
Why?
|
| Surgeons | 1 | 2015 | 287 | 0.320 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2023 | 33 | 0.320 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 321 | 0.320 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 645 | 0.320 |
Why?
|
| Middle Cerebral Artery | 3 | 2021 | 115 | 0.310 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2026 | 8 | 0.290 |
Why?
|
| Cerebral Angiography | 3 | 2026 | 108 | 0.290 |
Why?
|
| Adult | 20 | 2026 | 31734 | 0.290 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 64 | 0.270 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 683 | 0.270 |
Why?
|
| Angiography | 2 | 2020 | 188 | 0.250 |
Why?
|
| Basilar Artery | 1 | 2026 | 18 | 0.240 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2020 | 474 | 0.230 |
Why?
|
| Anesthesia, Local | 1 | 2026 | 39 | 0.230 |
Why?
|
| Decompressive Craniectomy | 1 | 2025 | 11 | 0.230 |
Why?
|
| Recovery of Function | 2 | 2024 | 452 | 0.220 |
Why?
|
| Femoral Artery | 1 | 2025 | 136 | 0.220 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2025 | 115 | 0.210 |
Why?
|
| Neuroimaging | 2 | 2025 | 406 | 0.210 |
Why?
|
| Radiosurgery | 2 | 2016 | 135 | 0.210 |
Why?
|
| Reperfusion | 2 | 2020 | 26 | 0.210 |
Why?
|
| Catheterization, Peripheral | 1 | 2026 | 129 | 0.210 |
Why?
|
| Carotid Artery, Internal | 3 | 2024 | 56 | 0.200 |
Why?
|
| Skull | 3 | 2023 | 154 | 0.190 |
Why?
|
| Blood Coagulation Disorders | 1 | 2024 | 105 | 0.190 |
Why?
|
| Moyamoya Disease | 1 | 2023 | 42 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 18 | 0.190 |
Why?
|
| Balloon Embolectomy | 2 | 2018 | 2 | 0.190 |
Why?
|
| Fetal Stem Cells | 2 | 2012 | 5 | 0.190 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 63 | 0.190 |
Why?
|
| Time Factors | 7 | 2026 | 6285 | 0.180 |
Why?
|
| Combined Modality Therapy | 3 | 2025 | 1261 | 0.180 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2021 | 8 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2021 | 18 | 0.180 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 100 | 0.180 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2012 | 82 | 0.180 |
Why?
|
| Patient Selection | 1 | 2025 | 726 | 0.180 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 19 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 35 | 0.170 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 60 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2012 | 110 | 0.170 |
Why?
|
| Temporal Arteries | 1 | 2021 | 31 | 0.170 |
Why?
|
| Pandemics | 4 | 2021 | 1165 | 0.170 |
Why?
|
| New York City | 4 | 2021 | 64 | 0.170 |
Why?
|
| Brain Infarction | 1 | 2020 | 28 | 0.170 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 20 | 0.160 |
Why?
|
| Pons | 1 | 2020 | 34 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 26 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2020 | 13 | 0.160 |
Why?
|
| Skull Base | 2 | 2020 | 48 | 0.160 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 40 | 0.160 |
Why?
|
| Empirical Research | 1 | 2019 | 10 | 0.160 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 34 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 1300 | 0.150 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 47 | 0.150 |
Why?
|
| Arteriovenous Fistula | 1 | 2020 | 55 | 0.150 |
Why?
|
| Catheters | 3 | 2024 | 84 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 114 | 0.150 |
Why?
|
| Glioblastoma | 1 | 2022 | 347 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 2965 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 144 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2020 | 234 | 0.140 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 265 | 0.140 |
Why?
|
| Spinal Diseases | 1 | 2018 | 47 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2025 | 3135 | 0.140 |
Why?
|
| Glioma | 1 | 2022 | 500 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 237 | 0.140 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 109 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2014 | 272 | 0.130 |
Why?
|
| Epidermal Cyst | 1 | 2016 | 17 | 0.120 |
Why?
|
| Neuroendoscopy | 1 | 2016 | 32 | 0.120 |
Why?
|
| Nervous System Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2020 | 1104 | 0.120 |
Why?
|
| Dermoid Cyst | 1 | 2016 | 36 | 0.120 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 35 | 0.120 |
Why?
|
| Epilepsy | 2 | 2016 | 898 | 0.120 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2015 | 11 | 0.110 |
Why?
|
| Recurrence | 3 | 2026 | 1487 | 0.110 |
Why?
|
| Models, Anatomic | 1 | 2016 | 107 | 0.110 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 35 | 0.110 |
Why?
|
| Printing, Three-Dimensional | 1 | 2016 | 88 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 550 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1141 | 0.110 |
Why?
|
| Risk Factors | 6 | 2026 | 10998 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3453 | 0.110 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 146 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2015 | 181 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 708 | 0.100 |
Why?
|
| Thrombosis | 1 | 2018 | 495 | 0.100 |
Why?
|
| Young Adult | 5 | 2016 | 10108 | 0.100 |
Why?
|
| Patients | 1 | 2015 | 122 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2025 | 353 | 0.100 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 58 | 0.100 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 61 | 0.100 |
Why?
|
| Cadaver | 1 | 2013 | 121 | 0.100 |
Why?
|
| Hydrocephalus | 1 | 2016 | 292 | 0.100 |
Why?
|
| Data Collection | 1 | 2015 | 372 | 0.100 |
Why?
|
| Physician's Role | 1 | 2015 | 165 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2026 | 6522 | 0.100 |
Why?
|
| Osteoarthritis, Spine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 321 | 0.090 |
Why?
|
| Age Distribution | 1 | 2013 | 429 | 0.090 |
Why?
|
| Alberta | 2 | 2023 | 64 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 762 | 0.090 |
Why?
|
| Braces | 1 | 2012 | 17 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2012 | 67 | 0.090 |
Why?
|
| Arachnoid Cysts | 1 | 2012 | 10 | 0.090 |
Why?
|
| Pain | 1 | 2015 | 439 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2013 | 227 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 870 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 397 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2014 | 357 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2016 | 1457 | 0.090 |
Why?
|
| Hypothalamic Diseases | 1 | 2012 | 40 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 739 | 0.090 |
Why?
|
| Hamartoma | 1 | 2012 | 52 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2026 | 5122 | 0.090 |
Why?
|
| Hospitalization | 2 | 2020 | 1942 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 395 | 0.080 |
Why?
|
| United States | 4 | 2026 | 11827 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 505 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 236 | 0.080 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2011 | 64 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 974 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 3095 | 0.080 |
Why?
|
| Animals | 5 | 2024 | 34460 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 310 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 548 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 721 | 0.070 |
Why?
|
| Adolescent | 4 | 2016 | 21008 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 886 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 5298 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2026 | 3928 | 0.060 |
Why?
|
| Myocardium | 1 | 2011 | 876 | 0.060 |
Why?
|
| Prevalence | 1 | 2013 | 2697 | 0.060 |
Why?
|
| Child | 6 | 2016 | 26332 | 0.060 |
Why?
|
| Mechanical Thrombolysis | 1 | 2025 | 10 | 0.060 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2024 | 2 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2025 | 170 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2026 | 214 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1002 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1951 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2025 | 182 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 197 | 0.050 |
Why?
|
| Incidence | 2 | 2023 | 3352 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2014 | 1217 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2023 | 13 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 46 | 0.050 |
Why?
|
| Anterior Cerebral Artery | 1 | 2022 | 6 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 79 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 70 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 51 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 87 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 8 | 0.050 |
Why?
|
| Walruses | 1 | 2021 | 1 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 274 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 4684 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 60 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 205 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2012 | 382 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3415 | 0.040 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2020 | 25 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 130 | 0.040 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 10 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 26 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 39 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 92 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2020 | 41 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 70 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 32 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2020 | 76 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 74 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 53 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 139 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 130 | 0.040 |
Why?
|
| Aphasia | 1 | 2018 | 14 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 185 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 2869 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 284 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 838 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2023 | 976 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 85 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2026 | 3708 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 558 | 0.030 |
Why?
|
| Brain | 2 | 2022 | 3247 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2226 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2154 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 123 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1607 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2015 | 78 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 2015 | 80 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 4961 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1916 | 0.020 |
Why?
|
| Zygapophyseal Joint | 1 | 2012 | 4 | 0.020 |
Why?
|
| Neck Pain | 1 | 2012 | 20 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 11 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 420 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 227 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 297 | 0.020 |
Why?
|
| Headache | 1 | 2012 | 110 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 13332 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 824 | 0.020 |
Why?
|
| Calcinosis | 1 | 2012 | 187 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 15066 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 232 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 772 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2012 | 197 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 460 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 844 | 0.020 |
Why?
|
| Pregnancy | 2 | 2012 | 7577 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 471 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 569 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1252 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2011 | 391 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1519 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2011 | 678 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2368 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2011 | 875 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2963 | 0.010 |
Why?
|
| Mice | 2 | 2012 | 18504 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8604 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 4762 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 2442 | 0.010 |
Why?
|